April 20, 2014 8:45 PM ET

Biotechnology

Company Overview of FORMA Therapeutics, Inc.

Company Overview

FORMA Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of therapeutics for Achilles heels in human cancers. The company has strategic collaborations with deCODE Biostructures, Inc.; Eisai, Inc.; and Celgene Corporation. FORMA Therapeutics, Inc. was formerly known as Forma Pharmaceuticals, Inc. and changed its name to FORMA Therapeutics, Inc. in 2008. The company was incorporated in 2007 and is based in Cambridge, Massachusetts. It has research operations in Cambridge, Massachusetts; Branford, Connecticut; Singapore; and Beijing, China.

790 Memorial Drive

Suite 2B

Cambridge, MA 02139

United States

Founded in 2007

Phone:

617-679-1970

Key Executives for FORMA Therapeutics, Inc.

Co-Founder
Co-Founder and Vice President of Discovery Biology
Age: 51
Vice President of Finance
Chief Operating Officer
Age: 49
Compensation as of Fiscal Year 2013.

FORMA Therapeutics, Inc. Key Developments

FORMA Therapeutics and Celgene Corporation Announce Novel and Expansive Multi-Year Strategic Alliance

FORMA Therapeutics announced a second strategic collaboration and option agreement with Celgene Corporation. This new collaboration will enable FORMA to extend its unique capabilities across broad areas of chemistry and biology. Upon signing the agreement, FORMA received an upfront cash payment of $225 million, and the parties entered into a collaboration with a term of 3 1/2 years. In addition to the 3 1/2 year collaboration, Celgene has the option to enter into up to two additional collaborations with terms of two years each for additional payments totaling approximately $375 million.

FORMA Therapeutics Announces Advancement of Collaboration with Boehringer Ingelheim for Modulating Protein-Protein Interactions in the Treatment of Cancer

FORMA Therapeutics announced the achievement of several discovery milestones in their alliance with Boehringer Ingelheim (BI) for the discovery of novel drug candidates against protein-protein interactions (PPI) for the treatment of cancer. As part of the PPI alliance, BI has formally internalized novel compounds for an oncology-relevant PPI program from FORMA. Further, FORMA will continue to conduct screening within the alliance, has expanded chemistry resourcing to prosecute validated scaffolds, and will continue to further interrogate additional targets named within the agreement. FORMA will receive undisclosed payments as part of these recent scientific advancements.

FORMA Therapeutics Appoints Christopher Dinsmore as Vice President, Medicinal and Computational Chemistry

FORMA Therapeutics announced that Christopher Dinsmore, Ph.D., has been appointed to the position of Vice President, Medicinal and Computational Chemistry. Dr. Dinsmore joins the company after a distinguished 19 year career at Merck & Co. Inc., where he helped build the Merck Research Laboratory in Boston. Prior to joining the company, Dr. Dinsmore was Executive Director of Discovery Chemistry at Merck, where he led the discovery and advancement of seven compounds evaluated in clinical trials as well as several additional preclinical candidates.

Similar Private Companies By Industry

Company Name Region
Athenix Corp. United States
Selecta Biosciences, Inc. United States
AMBA Biosciences, LLC United States
Nomadic Systems, Inc. United States
Caisson Biotech, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FORMA Therapeutics, Inc., please visit www.formatherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.